Why the First Clinical Cure for HIV Will Likely be Developed in Maryland

Published on :

Why the First Clinical Cure for HIV Will Likely be Developed in Maryland By Chris Frew | September 18, 2023 As was true in the 1980s, Maryland’s DNA Valley remains [….]

CEO Jeff Galvin and American Gene Technologies’ Spinoff, AddImmune, Offer Hope to End the HIV Epidemic

Published on :

CEO Jeff Galvin and American Gene Technologies’ Spinoff, AddImmune, Offer Hope to End the HIV Epidemic August 9, 2023 This transcript originally appeared via Think – a national technology and operations [….]

American Gene Technologies Celebrates Phase I Success of Experimental HIV Cell Therapy

Published on :

American Gene Technologies Celebrates Phase I Success of Experimental HIV Cell Therapy By Alex KeownJune 13, 2023 American Gene Technologies (AGT) is one step closer to making history with a [….]

American Gene Technologies Spins Off Addimmune as a Separate Company With a Focus on Curing HIV

Published on :

American Gene Technologies Spins Off Addimmune as a Separate Company With a Focus on Curing HIV By Alex KeownJune 9, 2023 Powered by promising Phase I results from its HIV [….]

5 Questions With Layla Ghaffari, Associate Scientist at American Gene Technologies

Published on :

5 Questions With Layla Ghaffari, Associate Scientist at American Gene Technologies June 6, 2023 “5 Questions With…” is a recurring BioBuzz series where we reach out to interesting people to [….]

Upcoming 3rd Annual BioBuzz Awards to Celebrate Winners from Maryland, Philadelphia

Published on :

Upcoming 3rd Annual BioBuzz Awards to Celebrate Winners from Maryland, Philadelphia In addition to the reception, the event will also feature several panels comprised of esteemed local key opinion leaders [….]

In Conversation with Gaspar Canepa, PhD, Principal Scientist at American Gene Technologies®

Published on :

You likely know AGT best from their ongoing work to develop a potential HIV cure. Their lead candidate, AGT103-T, is currently in a Phase 1 trial and has shown encouraging data thus far both in patient safety and T cell responses. The company is currently planning for Phase 2.